---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-276718"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-06-22T12:00:17+00:00"
generated_at: "2026-06-22T12:06:53.798482+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines President R&D Steve Kelsey to retire Jan 2027; becomes senior advisor from July 2026

## Summary
- Steve Kelsey, M.D., president R&D, to retire effective Jan 4, 2027; will serve as senior advisor to CEO from July 1, 2026.
- Company intends to appoint Dr. Kelsey to board of directors upon retirement, subject to board approval.
- Annual meeting results: Class III directors Alexis Borisy and Mark Goldsmith elected; PwC ratified as auditor; say-on-pay approved.

## SEC filing metadata
- accession: 0001193125-26-276718
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-06-22T12:00:17+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/d123125d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-276718
- JSON: https://secwatch.observer/filing/0001193125-26-276718.json
- Plain text: https://secwatch.observer/filing/0001193125-26-276718.txt

## Key facts
- Executive change
  Steve Kelsey changed role as senior advisor to the chief executive officer at Revolution Medicines, Inc..
  - Action: transition
  - Role: senior advisor to the chief executive officer
  source text: Dr. Kelsey will transition from his role as the Company’s president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm
- Executive change
  Steve Kelsey departed as president, research and development at Revolution Medicines, Inc..
  - Action: retire
  - Role: president, research and development
  source text: On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his employment with the Company effective as of January 4, 2027.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm
- Shareholder Votes
  Revolution Medicines, Inc. shareholders approved Election of two Class III directors to hold office until the 2029 annual meeting at the 2026-06-18 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Nominee Votes For Votes Withheld Broker Non-Votes Alexis Borisy 127,181,172 33,660,532 20,813,641 Mark A. Goldsmith, M.D., Ph.D. 157,681,628 3,160,076 20,813,641
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm
- Shareholder Votes
  Revolution Medicines, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-18 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Votes For Votes Against Abstentions 181,309,783 206,306 139,256
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm
- Shareholder Votes
  Revolution Medicines, Inc. shareholders approved Non-binding advisory approval of named executive officer compensation at the 2026-06-18 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-18
  source text: Votes For Votes Against Abstentions Broker Non-Votes 155,110,825 5,554,146 176,733 20,813,641
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526276718/0001193125-26-276718-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.